Mitiglinide is an anti-diabetic/anti-hyperglycemic compound that increases insulin secretion and decreases plasma glucose in pancreatic β cells. The short action of mitiglinide mimics the in vivo duration and timing of insulin release. Mitiglinide decreases levels of FGF-21, altering glucose metabolism. Mitiglinide directly inhibits ATP-sensitive K+ channels and may also activate ryanodine (RyR) receptors, altering intracellular Ca2+ release.
| Cas No. | 145375-43-5 |
|---|---|
| Purity | ≥98% |
| Formula | 2(C19H24NO3)Ca |
| Formula Wt. | 668.88 |
| IUPAC Name | 4-(1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl)-2-benzyl-4-oxobutanoic acidInChI: InChI=1S/C19H25NO3/c21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14/h1-3,6-7,15-17H,4-5,8-13H2,(H,22,23) |
| Appearance | White to off white powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | M3577 Info Sheet PDF |
|---|
Phillippe HM, Wargo KA. Mitiglinide for type 2 diabetes treatment. Expert Opin Pharmacother. 2013 Oct;14(15):2133-44. PMID: 23992284.
Wang B, Yang G, Yang M, et al. Mitiglinide treatment may decreases plasma fibroblast growth factor-21 levels in individuals with new-onset T2DM. Cytokine. 2012 Feb;57(2):300-3. PMID: 22129626.
Phillippe HM, Wargo KA. Mitiglinide: a novel agent for the treatment of type 2 diabetes mellitus. Ann Pharmacother. 2010 Oct;44(10):1615-23. PMID: 20841518.
Shigeto M, Katsura M, Matsuda M, et al. Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum. J Pharmacol Exp Ther. 2007 Jul;322(1):1-7. PMID: 17409272.
